argenx SE
Laarderhoogtweg 25
Amsterdam 1101EB
Netherlands
31 10 703 8441
https://www.argenx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 1,148
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | CEO & Executive Director | 1.29M | 無 | 1972 |
| Mr. Karl Gubitz | Chief Financial Officer | 843.26k | 無 | 1970 |
| Ms. Karen Massey | Chief Operating Officer | 1.42M | 無 | 1979 |
| Mr. Filip Borgions | VP & Global Head of Technical Operations | 無 | 無 | 無 |
| Mr. Peter Ulrichts | Chief Scientific Officer | 無 | 無 | 1980 |
| Ms. Beth DelGiacco | VP and Global Head of Corporate Communications & Investor Relations | 無 | 無 | 無 |
| Ms. Malini Moorthy | General Counsel | 無 | 無 | 1970 |
| Mr. Arjen Lemmen M.Sc. | Vice President of Corporate Development & Strategy | 無 | 無 | 1985 |
| Mr. Marc Schorpion | Global Head of Human Resources | 無 | 無 | 1959 |
| Ms. Andria Wilk | Global Head of Quality | 無 | 無 | 1974 |
描述
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
公司管治
截至 2024年5月1日 止，argenx SE 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：3；董事會：2；股東權利：3；現金賠償：9。
